Zhong Guo Jing Ji Wang·2025-08-25 13:17Core Viewpoint - The financial performance of BGI Genomics (华大智造) in the first half of 2025 shows a decline in revenue and negative net profit, indicating ongoing challenges for the company in the market. Financial Performance Summary - In the first half of 2025, the company's operating revenue was 1.114 billion yuan, a year-on-year decrease of 7.9% [1] - The net profit attributable to shareholders was -104 million yuan, an improvement from -298 million yuan in the same period last year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -203 million yuan, compared to -324 million yuan in the previous year [1] - The net cash flow from operating activities was -150 million yuan [1] Historical Financial Data - In 2023 and 2024, the net profit attributable to shareholders was -607 million yuan and -601 million yuan, respectively [4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for the same years was -683 million yuan and -653 million yuan, respectively [4] Fundraising and Use of Proceeds - BGI Genomics raised a total of 3.602 billion yuan, with a net amount of 3.285 billion yuan after deducting issuance costs, exceeding the original plan by 756.7 million yuan [3] - The funds are intended for various projects, including the establishment of an intelligent manufacturing and R&D base, development of semiconductor-based gene sequencers and related reagents, and the construction of a marketing service center [3] Stock Performance - BGI Genomics was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 9, 2022, with an issuance of 41.32 million shares at a price of 87.18 yuan per share, currently trading below the issue price [2]